Skip to main content

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Actigraphy Improvement With Voxelotor (ActIVe) Study

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Actigraphy Improvement With Voxelotor (ActIVe) Study

TTVR Early Feasibility Study

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about TTVR Early Feasibility Study

Cancer and Blood Pressure Management, CARISMA Study

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Cancer and Blood Pressure Management, CARISMA Study

TRISCEND II Pivotal Trial

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about TRISCEND II Pivotal Trial

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Cas

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Cas

ACTIV-3: Therapeutics for Inpatients With COVID-19

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about ACTIV-3: Therapeutics for Inpatients With COVID-19

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 202
  • Page 203
  • Page 204
  • Page 205
  • Page 206
  • Page 207
  • Page 208
  • Page 209
  • Page 210
  • …
  • Next page Next
  • Last page Last
Subscribe to